Floatz logo

Elafibranor

Cardiovascular Diseases

GenfitSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

60 Active assets in the Cardiovascular Diseases cohort.

Asset / SponsorPhaseRating
Acetylsalicylic Acid
AstraZeneca
Phase 4BBB
Liraglutide
University of Sao Paulo General Hospital
Phase 4BBB
Lipitor
Duke University
Phase 4BBB
Rosuvastatin
Nanjing First Hospital, Nanjing Medical University
Phase 4BBB
SIMVASTATIN
McMaster University
Phase 4BBB

View all 50 →

Same molecule, other indications

Elafibranor is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative ·
66 / 100
View asset →
Abdominal ObesityDormant
BB
Indicative ·
66 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →